Alaabta

Niacin (nicotinic acid) monotherapy ahaan waxay yarayn kartaa halista cudurada xididada xididada, laakiin qaabkeeda ficilku wali waa muran ka taagan yahay, waxaana laga yaabaa inaanay ku xidhnayn saamaynta habaysan ee wax ka beddelka dufanka.Niacin ayaa dhawaan la muujiyay si loo hagaajiyo shaqada endothelial iyo dib u soo kabashada xididdada xididada, oo ka madax bannaan hagaajinta dyslipidemia, moodooyinka jiirka ee dhaawaca xididada iyo cudurrada dheef-shiid kiimikaadka.Sida horudhaca biosynthetic ee suurtagalka ah ee NAD(+), niacin waxay ka dhalin kartaa faa'iidooyinkan xididdada NAD (+) -ku-tiirsanaanta, jawaabaha dhexdhexaadinta sirtuin (SIRT).Beddelkeeda, niacin waxa laga yaabaa inay ku dhaqdo soo-qabteheeda, GPR109A, si kor loogu qaado shaqada endothelial, inkasta oo unugyada endothelial aan la garanayn inay muujiyaan reseptor-kan.Waxaan ku qiyaasnay ​​in niacin ay si toos ah u wanaajiso shaqada unugyada endothelial inta lagu jiro soo-gaadhista xaaladaha lipotoxic waxaana la raadinay si loo go'aamiyo hababka suurtagalka ah ee ku lug leh. fiirsashada yar ee niacin (10 μM), ama nicotinamide mononucleotide (NMN) (1 μM), horudhac toos ah oo NAD(+) ah.In kasta oo niacin iyo NMN labaduba ay wanaajiyeen samaynta tuubada HMVEC inta lagu jiro culeyska xad-dhaafka ah, NMN kaliya ayaa kordhay NAD(+) gacanta iyo dhaqdhaqaaqa SIRT1.Waxaan sidoo kale aragnay in HMVEC ay muujinayso GRP109A.Dhaqdhaqaaqa soo-dhoweyntan oo leh acifran ama MK-1903 ayaa dib u habeyn ku sameeyay niacin-ku-soo-kordhinta samaynta tuubada HMVEC, halka GPR109A siRNA ay hoos u dhigtay saameynta niacin.Niacin, oo ah feejignaan hooseeya, waxay hagaajisaa shaqada HMVEC angiogenic ee hoos yimaada xaaladaha lipotoxic, waxay u badan tahay inay ka madax bannaan tahay NAD ( +) biosynthesis iyo firfircoonida SIRT1, laakiin taa beddelkeeda iyada oo loo marayo firfircoonida soo-dhoweynta niacin.